


INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
CT-2711 NP
APPLICATION NO.
10/637,099
APPLICANT
ROMINE ET AL.
FILING DATE
AUGUST 8, 2003

Group 1626



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
MC	AA	6,323,180 B1	11/27/01	Llinas-Brunet et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

yz	AR	Lauer et al. (2001) New England Journal of Medicine, Vol. 345, No. 1, Pages 41-52
yz	AS	Poynard et al. (1998) The Lancet, Vol. 352, Pages 1426-1432
yz	AT	Zeuzem et al. (2000) The New England Journal of Medicine, Vol. 343, No. 23, Pages 1666-1672

EXAMINER

Hong cl


DATE CONSIDERED

1-27-2006

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.
CT-2711 NP
APPLICATION NO.
10/637,099
APPLICANT
ROMINE ET AL.
FILING DATE
AUGUST 8, 2003

Sheet 2 of 2

Group 1626

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

yz	AA	De Clercq. (2001) Journal of Clinical Virology, Vol 22, Pages 73-89
yz	AB	Tan et al. (2001) Virology, Vol. 284, Pages 1-12
yz	AC	Park et al. (2003) The Journal of Biological Chemistry, Vol. 278, No. 33, Pages 30711-30718
	AD	
	AE	
	AF	
	AG	
	AH	
	AI	
	AJ	
	AK	
	AL	
	AM	
	AN	

EXAMINER

Hong cl

DATE CONSIDERED

1-27-2006

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

COMPLETE IF KNOWN

(use as many sheets as necessary)

2

10/637099

08/08/2003

Jeffrey Lee Romine

~~1614~~ 1626

CT2711-US - NP

[illegible][illegible]

1-27-2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/637099
Filing Date	08/08/03
First Named Inventor	Jeffrey Lee Romine
Art Unit	4814 1626
Examiner Name	
Attorney Docket Number	CT2711-US - NP

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
yz	2AA	SARRAZIN, C. et al., "Mutations in the Protein Kinase-Binding Domain of the NS5A Protein in Patients Infected with Hepatitis C Virus Type 1a Are Associated with Treatment Response," The Journal of Infectious Diseases, Vol. 181, pp. 432-441 (2000)	
yz	2AB	FRANGEUL, L. et al., "Mutations in NS5A Region of Hepatitis C Virus Genome Correlate With Presence of NS5A Antibodies and Response to Interferon Therapy for Most Common European Hepatitis C Virus Genotypes," Hepatology, Vol. 28, No. 6, pp. 1674-1679 (1998)	
yz	2AC	WOITAS, R.P. et al., "Differential expansion of T-cell receptor variable beta subsets after antigenic stimulation in patients with different outcomes of hepatitis C infection," Immunology, Vol. 106, pp. 419-427 (2002)	
yz	2AD	WANG, Y.S. et al., "Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications," Advanced Drug Delivery Reviews, Vol 54, pp. 547-570 (2002)	

Examiner Signature

Yong cl

Date Considered

1-27-2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant